Dissolved molecular hydrogen (H_2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity
Nakayama M, Zhu WJ, Watanabe K, Gibo A, Sherif AM, Kabayama S, Ito S. · BMC nephrology. 2017;18(1):327.
What kind of evidence is this?
Preclinical
Controlled animal and cell study
Metabolic and lipid health
Other forms
Not reported in this record.
Not reported in this record.
Methods at a glance
rats, tissue, rat, cells used to study metabolic and lipid health.
Preclinical study; group or assay counts reported in the full text include n=9, n=11, n=8.
10 days
Full text reports an injected or infused H₂ intervention. Detected intervention quantities or schedules: 2.5%, 400 ppb, 400 ppm, 10 days, 1.5 ppm.
an injected or infused H₂ intervention — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 2.5%, 400 ppb, 400 ppm, 10 days, 1.5 ppm. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “A significant increase in the number of vimentin-positive cells were observed in the PD group compared with the control and H_2PD groups (5.9 ±…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. Funding or grant information is reported in the full article. The full article contains a conflict, commercial-support or supplied-product declaration; consult the source wording.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 29089029 · DOI: 10.1186/s12882-017-0741-0
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10